Series
Radiotherapy
Status
Published
Date
Number of report
029
Proton Therapy
Ask the expert
The report presents a summary of reimbursement situation for proton therapy in European countries.
Sample pages are provided for an older version of the report. Before delivery to the client, the report is updated to the current state (e.g., 2022 coding, tariffs, and policy considerations).
The analysis covers the application of proton therapy in ocular tumors in adults and pediatric medulloblastoma.
The analysis is provided for the session and out-patient treatment, including both preparation and delivery of proton therapy. The only reimbursement within public / statutory health insurance systems is considered.
The report includes essential information about reimbursement, including:
- Brief country-specific overview of reimbursement system
- Procedure coding for technology
- Diagnosis coding
- Payment mechanism for technology
- Reimbursement tariffs for technology
- Restrictions on indications or scenarios for the use of technology
- Policy considerations by payers and policy-makers about technology
Reimbursement information is provided for the following geographies:
- Austria
- Belgium
- Denmark
- England (UK)
- Finland
- France
- Germany
- Italy
- The Netherlands
- Norway
- Sweden
- Switzerland
It is also possible to add analysis in Czech Republic, Finland, Hungary, Romania, Russia and Turkey.
Manufacturers of equipment for proton therapy include:
- Hitachi Medical Systems (PROBEAT-RT)
- IBA (Proteus ONE, Proteus Plus)
- Mevion (MEVION S250)
- Sumitomo Heavy Industries (HM series)
- Varian Medical Systems (ProBeam, ProBeam Compact, ProBeam Multi-Room)
Table of content
1. Introduction and summary
2. Executive summary table
3. Contents
4. Abbreviations
5. What’s new
6. Methodology
7. Reimbursement analysis in Austria
7.1. Overview of the reimbursement system
7.2. Reimbursement for proton therapy
7.2.1. Policy considerations
7.2.2.1. Health technology assessments by LBI-HTA
8. Reimbursement analysis in Belgium
8.1. Overview of the reimbursement system
8.2. Reimbursement for proton therapy
8.2.1. Procedure coding
8.2.2. Policy considerations by the INAMI/RIZIV
8.2.3.1. Health technology assessments by KCE
9. Reimbursement analysis in Denmark
9.1. Overview of the proton therapy
9.2. Reimbursement for intensity modulated radiotherapy
10. Reimbursement analysis in England
10.1. Overview of the reimbursement system
10.2. Reimbursement for proton therapy
10.2.1. Commissioning of proton therapy
10.2.2. Health technology assessments by NICE
11. Reimbursement analysis in Finland
11.1. Overview of the reimbursement system
11.2. Reimbursement for proton therapy
12. Reimbursement analysis in France
12.1. Overview of the reimbursement system
12.2. Reimbursement for proton therapy
12.2.1. Procedure coding
12.2.2. Diagnosis coding
12.2.3. Payment mechanism and reimbursement tariffs
12.2.4. Policy considerations by HAS
13. Reimbursement analysis in Germany
13.1. Overview of the reimbursement system
13.2. Reimbursement for proton therapy
13.2.1. Procedure coding
13.2.2. Diagnosis coding
13.2.3. Payment mechanism and reimbursement tariffs
13.2.4. Policy considerations by G-BA
14. Reimbursement analysis in Italy
14.1. Overview of the reimbursement system
14.2. Reimbursement for proton therapy
14.2.1. Procedure coding
14.2.2. Payment mechanism and reimbursement tariffs
14.2.3. Policy considerations
15. Reimbursement analysis in the Netherlands
15.1. Overview of the reimbursement system
15.2. Reimbursement for proton therapy
15.2.1. Procedure coding
15.2.2. Payment mechanism and reimbursement tariffs
15.2.3. Policy considerations by Dutch Healthcare Institute (ZIN)
16. Reimbursement analysis in Norway
16.1. Overview of the reimbursement system
16.2. Reimbursement for proton therapy
16.2.1. Procedure coding
16.2.2. Diagnosis coding
16.2.3. Payment mechanism and reimbursement tariffs
16.2.4. Policy considerations
17. Reimbursement analysis in Sweden
17.1. Overview of the reimbursement system
17.2. Reimbursement for proton therapy
17.2.1. Procedure coding
17.2.2. Diagnosis coding
17.2.3. Payment mechanism and reimbursement tariffs
17.2.4. Policy considerations
18. Reimbursement analysis in Switzerland
18.1. Overview of the reimbursement system
18.2. Reimbursement for proton therapy
18.2.1. Procedure coding
18.2.2. Diagnosis coding
18.2.3. Payment mechanism and reimbursement tariffs
18.2.4. Policy considerations
19. Summary of procedure codes
20. Summary of reimbursement codes and tariffs
21. Disclaimer
07
Apr 2023
In March 2023, the National Institute for Health and Care Excellence (NICE) published two new Interventional Procedure Guidance (percutaneous transluminal renal sympathetic denervation for resistant hypertension, endoluminal gastroplication for gastro-oesophageal reflux disease), three new Health Technology Evaluations via piloted early value assessment approach (CaRi-Heart for predicting cardiac risk in suspected coronary artery disease, ProKnow cloud-based system for radiotherapy data storage, and Genedrive MT-RNR1 ID Kit for detecting a genetic variant), and two new MedTech Innovation Briefings (QBTest and BPMpathway). No new clinical guidelines were published.
Read more16
Mar 2023
In January-February 2023, Health Technology Wales published sixteen Medtech-related Topic Exploration Reports (TER), including stereotactic radiosurgery, percutaneous implantation of pulmonary artery pressure sensors, ambulatory patch ECG devices, and others; however, Health Technology Wales will not proceed with full appraisals on these topics. No Guidance was released for Medtech in January-February 2023.
Read more24
Feb 2023
In February 2023, the Clinical Coding and Schedule Development (CCSD) working group, which develops and maintains procedural and diagnostics nomenclatures for private payers in England, published Bulletins 188 and 084 with changes to be implemented no later than March 23, 2023. Five new procedure codes (concerning interventional radiology, robotic surgery, and radiotherapy) and one new diagnostic code were introduced.
Read more15
Feb 2023
In February 2023, it was announced that the Basque Office for Health Technology Assessment (OSTEBA) initiated several HTAs, including evaluations in the e-health, radiology, nephrology and urology, cardiovascular, IVD, obstetrics and gynecology, diagnostic imaging, radiotherapy, neurovascular, ENT, interventional radiology, surgical procedures, and some other fields.
Read more12
Jan 2023
In December 2022, the National Institute for Health and Care Excellence (NICE) published one new Medical Technologies Guidance (Memokath 051 Ureter stent for ureteric obstruction) and one MedTech Innovation Briefing (PromarkerD). Also, two new clinical guidelines were published, and one was updated.
Read more